Mission

The Population Studies and Disparities Research (PSDR) Program is committed to identifying key genetic and behavioral risk factors underlying disease onset and progression, and developing and testing novel intervention strategies to reduce risk and improve diagnosis, treatment and outcomes with an emphasis on reducing and/or eliminating cancer health disparities among populations contained within our catchment area.

Scientific Themes

The PSDR Program themes encompass research to reduce and eliminate disparities across the cancer experience of adult and pediatric populations, and include a diversity of race/ethnic groups. 

  • Investigate the distribution and determinants of cancer and cancer risk, survivorship and outcomes in a unique and large underserved population.
  • Develop and test interventions focused on patients, family members, physician behaviors and system-level drivers to reduce health disparities in cancer prevention, treatment, survivorship, and end-of-life outcomes.

Program Activities

Members of the Population Studies & Disparities Research Program regularly interact in several ways to develop scientific directions and implement strategic planning efforts including:

  • A PSDR Program Committee meets monthly to discuss strategic directions, research collaborations, plan seminars and retreats, and address general programmatic issues as they arise
  • Monthly faculty meetings to discuss epidemiological and communication/behavioral research in progress
  • Monthly PSDR research meetings and seminar presentations directed at the entire program membership
  • Yearly thematic research retreats are held with distinguished national speakers invited to give keynote addresses and faculty and post doctoral fellows presenting their latest research findings
  • Karmanos-wide annual scientific retreat
  • PSDR members are engaged in several Karmanos Research Groups to develop program projects applications.
  • A major effort underway is the PSDR Survivorship Working Group, this team is conducting a pilot cohort study of Karmanos-based African American and white cancer cases and family members to provide preliminary data for a planned P01, to be submitted in 2015
  • Members participate in the Karmanos Lung Cancer Research Group, the Lung Cancer SPORE planning group, the Breast Cancer Research Group and the Prostate Cancer Research Group

Surveillance, Epidemiology, and End Results Program (SEER)

The metropolitan Detroit area is home to a highly diverse and medically underserved population. As part of the original SEER program of nine registries dating back to 1973, we contribute approximately 38% of the national cancer incidence and survival data for African Americans. The SEER registry is not only used for descriptive studies; it provides a population-based source of cases for case-control and case-case comparisons. There are ~25,000 new cancers diagnosed in Metropolitan Detroit each year, with about 25% of those being diagnosed in African Americans. In addition to the large African American population, this area is home to the largest concentration of Arab Americans in the United States. This population diversity provides a remarkable opportunity for the study of race/ethnicity related health disparities. All of the research described is conducted in this context and includes substantial numbers of minorities.

Program Leaders

  • Jennifer Beebe-Dimmer, Ph.D., MPH
    Jennifer Beebe-Dimmer, Ph.D., MPH

    Program Leader, Population Studies and Disparities Research Program
    Director, Epidemiology Research Core
    Barbara Ann Karmanos Cancer Institute
    Professor, Department of Oncology
    Wayne State University School of Medicine
    dimmerj@wayne.edu

  • Lauren Hamel, Ph.D., MBA

    Co-Program Leader, Population Studies and Disparities Research
    Barbara Ann Karmanos Cancer Institute
    Associate Professor, Department of Oncology
    Wayne State University School of Medicine
    lauren.hamel@wayne.med.edu

The Latest From Karmanos Cancer Institute

News

Karmanos Researcher Co-discovered Compound, Led to First FDA-Approved Therapy for Rare Brain Cancer

For Gen Sheng Wu, Ph.D., a member of the Molecular Therapeutics Research Program at the Barbara Ann Karmanos Cancer Institute and professor in the...

Read More

Prostate Cancer Screening: Why the Conversation Matters

Among American men, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death after lung cancer. ...

Read More

Karmanos Cancer Institute Recognizes Four Cancer Awareness Months During September

The  Barbara Ann Karmanos Cancer Institute , along with cancer centers and other organizations across the nation, recognizes and promotes awa...

Read More
News

105.9 KISS FM | Getting a Second Opinion at Karmanos

Listen Now

WJR | Karmanos Cancer Institute Continues Its Community Education Series

Listen Now

WXYT 97.1 The Ticket | ‘Get a Mammogram’

Listen Now